1. Introduction {#sec1-molecules-22-01590}
===============

*Selaginella tamariscina* (Beauv.) which belongs to Selaginellaceae, has been traditionally used in treating blood in excrement, hematuria, inflammation, chronic hepatitis, and hyperglycemia in the Orient, especially in China \[[@B1-molecules-22-01590],[@B2-molecules-22-01590]\]. A number of alkaloids, flavonoids, lignans, selaginellins, phenolics, and terpenoids were reported as chemical constituents of *S. tamariscina* \[[@B3-molecules-22-01590]\]. Among these constituents, selaginellins are another group of polyphenolics with a p-quinone methide unit and an alkynylphenol carbon skeleton \[[@B4-molecules-22-01590]\]. Pharmacological studies demonstrate that selaginellins have been known to have anticancer \[[@B5-molecules-22-01590],[@B6-molecules-22-01590],[@B7-molecules-22-01590]\], antidiabetic \[[@B8-molecules-22-01590],[@B9-molecules-22-01590]\], antimicrobial \[[@B10-molecules-22-01590],[@B11-molecules-22-01590]\], antioxidant \[[@B12-molecules-22-01590],[@B13-molecules-22-01590]\], antihyperlipidemic \[[@B13-molecules-22-01590]\], and neuroprotective \[[@B14-molecules-22-01590]\] activities.

Use of botanical drugs to prevent common disease is on the rise among the global population \[[@B15-molecules-22-01590]\]. Since botanical drugs share the same drug metabolizing enzymes with commonly used commercial drugs, the potential for herb--drug interaction is substantial \[[@B16-molecules-22-01590]\]. Several medicinal herbs and foods, including St. John's wort \[[@B17-molecules-22-01590]\] and grapefruit juice \[[@B18-molecules-22-01590]\] as well as their active constituents (hyperforin \[[@B19-molecules-22-01590]\] and bergamottin \[[@B20-molecules-22-01590]\]) have been reported to cause severe drug interactions. Undoubtedly, the early evaluation of herb--drug interactions is necessary to prevent potential dangerous clinical outcomes.

Modulation of drug-metabolizing enzymes is one of the important causes of drug--drug or herb--drug interaction. Among the numerous drug-metabolizing enzymes, cytochrome P450s (P450s) and uridine 5′-diphosphoglucuronosyltransferases (UGTs), which are responsible for the metabolic clearance of 90% of commercial drugs, have been shown to a play key roles in drug metabolism and drug interactions \[[@B21-molecules-22-01590]\]. For example, bergamottin is reported to increase the blood concentration of drugs through inhibition of hepatic CYP3A activity, thereby enhancing the toxicity of drugs such as atorvastatin, felodipine, and verapamil \[[@B22-molecules-22-01590]\]. Pre-treatment with psoralidin, which has inhibitory potential against UGT1A1-mediated SN-38 glucuronidation (Ki = 5.8 μM), was shown to increase the toxicity of irinotecan \[[@B23-molecules-22-01590]\]. Accordingly, P450- and UGT-mediated drug interactions are even more critical.

Therefore, modulation of selaginellins on P450 and UGT activities may result in potential increase of the systemic exposures of co-administered drugs. To the best of our knowledge, however, no previous study has reported the modulatory effects of selaginellins against human P450 and UGT activities. Here, we investigated the inhibitory potential of two selaginellins ([Figure 1](#molecules-22-01590-f001){ref-type="fig"}) on ten P450- and six UGT-isoform activities in human liver microsomes (HLMs) using cocktails of P450 or UGT probe substrates to evaluate the possibility of drug interactions of selaginellins.

2. Results and Discussion {#sec2-molecules-22-01590}
=========================

In the present study, we investigated the inhibitory effect of two selaginellins against ten cytochrome P450 isoforms and six UGT isoforms using human liver microsomes ([Figure 2](#molecules-22-01590-f002){ref-type="fig"}). The results showed that selaginellin inhibited most of the P450 and UGT isoforms tested in a concentration-dependent manner. The inhibitory potential of selaginellins is categorized into high (IC~50~ \< 1 μM), medium (1 μM \< IC~50~ \< 10 μM), and low (IC~50~ \> 10 μM) classes based on Krippendorff's criteria \[[@B24-molecules-22-01590]\].

Selaginellin and selaginellin M had high inhibitory potential for CYP2C8-mediated amodiaquine *O*-demethylation ([Table 1](#molecules-22-01590-t001){ref-type="table"}), respectively, indicating that herbal drugs containing selaginellins may be used carefully with drugs metabolized by CYP2C8, such as anti-cancer drugs (paclitaxel and sorafenib), antidiabetics (repaglinide), and diuretics (torsemide) in order to avoid drug interactions \[[@B25-molecules-22-01590]\]. The inhibitory potential of these two selaginellins on CYP2C8 (IC~50~ \< 1 μM) were lower than that of troglitazone (IC~50~ = 2.3 μM \[[@B26-molecules-22-01590]\]) and quercetin (IC~50~ = 7.2 μM \[[@B27-molecules-22-01590]\]). Their inhibitory potentials, however, were less potent than montelukast, an strong CYP2C8 inhibitor (IC~50~ = 0.019 μM \[[@B28-molecules-22-01590]\]).

Two selaginellins also showed medium inhibitory potential on CYP2C9-catalyzed tolbutamide hydroxylation, CYP2J2-catalyzed astemizole *O*-demethylation, UGT1A1-catalyzed SN-38 glucuronidation, and UGT1A3-catalyzed chenodeoxycholic acid glucuronidation activities (IC~50~ \< 5 μM). CYP2C8, CYP2C9, and CYP2J2 metabolize approximately 4.7, 12.8, and 3% of clinically used drugs (*n* = 248), respectively \[[@B29-molecules-22-01590]\]. UGT1A1 also metabolizes approximately 17.3% of drugs (*n* = 237) which have glucuronidation as a clearance mechanism \[[@B30-molecules-22-01590],[@B31-molecules-22-01590]\]. Therefore, the inhibitory effect of selaginellins might be important for producing potential herb--drug interaction with drugs which undergo CPY2C8, CYP2C9, CYP2J2, and UGT1A1-mediated biotransformation; such drugs include glipizide, irinotecan, losartan, paclitaxel, tolbutamide, and warfarin \[[@B32-molecules-22-01590]\].

The effects on CYP1A1, CYP2A6, CYP2E1, and UGT1A6 activities were assumed to be a negligible (IC~50~ \> 25 μM) ([Table 1](#molecules-22-01590-t001){ref-type="table"}). These findings suggest that clinical interactions between these compounds and CYP1A1, CYP2A6, CYP2E1, or UGT1A6 would not occur.

*Selaginella tamariscina* (Beauv.) Spring has been used for centuries as a Traditional Chinese Medicine to treat various human diseases, including inflammation, human cancer, and hyperglycemia \[[@B33-molecules-22-01590]\]. Therefore, it might be used with anticancer or antidiabetic drugs which are metabolized by CYP2C8 (paclitaxel), CYP2C9 (tolbutamide), or UGT1A1 (irinotecan) \[[@B32-molecules-22-01590]\]. Selaginellins should be used carefully with these drugs to avoid drug interactions in cancer and diabetic patients.

3. Material and Methods {#sec3-molecules-22-01590}
=======================

3.1. Reagents {#sec3dot1-molecules-22-01590}
-------------

Alamethicin, β-Nicotinamide adenine dinucleotide phosphate (NADP^+^), chenodeoxycholic acid, trifluoperazine, *N*-acetylserotonin, mycophenolic acid, naloxone, naloxone-β-[d]{.smallcaps}-glucuronide, uridine 5′-diphosphoglucuronic acid (UDPGA), glucose-6-phosphate (G6P), glucose-6-phosphate dehydrogenase (G6PDH), terfenadine (internal standard (IS) for P450 assay), estrone-β-[d]{.smallcaps}-glucuronide (IS for UGT assay), phenacetin, dextromethorphan, coumarin, chlorzoxazone, bupropion, astemizole, amodiaquine, acetaminophen, hydroxybupropion, hydroxycoumarin, hydroxychlorzoxazone, and *N*-desethylamodiaquine were purchased from Sigma-Aldrich (St. Louis, MO, USA). Tolbutamide, omeprazole, midazolam, dextrorphan, 1′-hydroxymidazolam, hydroxyomeprazole, hydroxytolbutamide, *N*-acetylserotonin-β-[d]{.smallcaps}-glucuronide, chenodeoxycholic acid-24-acyl-β-glucuronide, mycophenolic acid-β-[d]{.smallcaps}-glucuronide, SN-38, and SN-38-glucuronide were obtained from Toronto research Chemicals (Toronto, ON, Canada). Solvents were LC-MS grade (Fisher Scientific Co., Pittsburgh, PA, USA) and the other chemicals were of the highest quality available. Pooled human liver microsomes (HLMs, H2630, mixed gender) were purchased from XenoTech (Lenexa, KS, USA). Selaginellins: Selaginellin and selaginellin M were isolated from *Selaginella tamariscina* (Beauv.) which was collected at Hon Ba Nature Reserve, Khanh Hoa province, Vietnam. The two compounds were purified and examined by HPLC to get 95% purity. Their chemical structures were identified by analyzing their NMR data which were in good agreement with those published in a previous report \[[@B8-molecules-22-01590]\].

3.2. Microsomal Incubation {#sec3dot2-molecules-22-01590}
--------------------------

### 3.2.1. Inhibitory Effects of Selaginellins on P450 Activity {#sec3dot2dot1-molecules-22-01590}

The inhibitory effects of two selaginellins on the metabolism of ten P450 probe substrates were evaluated using previously reported method with minor modification \[[@B27-molecules-22-01590]\]. Phenacetin *O*-deethylase, coumarin 7-hydroxylase, bupropion 4-hydroxylase, amodiaquine *N*-deethylase, tolbutamide 4-hydroxylase, omeprazole 5-hydroxylase, dextromethorphan *O*-demethylase, chlorzoxazone 6-hydroxylase and midazolam 1′-hydroxylase activities were determined as probe activities for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A2, respectively, using substrate cocktail incubation and tandem mass spectrometry ([Table 2](#molecules-22-01590-t002){ref-type="table"}). Selaginellins were dissolved in methanol. The final concentrations of organic solvent (methanol) for the cocktail incubation conditions in all experiments were 1.0% (*v*/*v*). In brief, the incubation mixtures containing pooled HLMs (0.25 mg/mL, H2630, Xenotech), P450 probe substrate cocktail, and inhibitor (0, 0.5, 2, 5, 20 and 50 μM) were preincubated at 37 °C for 5 min. The reaction was initiated by adding of the NADPH generating system (3.3 mM G6P, 1.3 mM β-NADP+, 3.3 mM MgCl~2~, and 1 unit/mL G6PDH) followed by incubation for 15 min at 37 °C. Next, each incubation was stopped by addition of 50 μL ice-cold acetonitrile containing terfenadine (IS). After mixing and centrifugation, aliquots were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as previous described \[[@B27-molecules-22-01590],[@B34-molecules-22-01590]\]. The CYP2J2 inhibitory effects of two selaginellins were also evaluated in pooled HLMs using previously reported method \[[@B35-molecules-22-01590],[@B36-molecules-22-01590]\]. In brief, the incubation reaction mixtures contained 0.25 mg/mL HLMs, astemizole (1 μM) and inhibitor (0.5--50 μM) in 0.1 mM phosphate buffer (pH 7.4). The reaction was initiated by the addition of NADPH-generating system and further incubated for 15 min. After reaction termination with cold acetonitrile containing 5 ng/mL terfenadine and centrifugation, aliquots were injected into a liquid chromatography-tandem mass spectrometry system (LC-MS/MS) as described previously \[[@B35-molecules-22-01590]\] ([Table 2](#molecules-22-01590-t002){ref-type="table"}). All microsomal incubations were performed in triplicate.

### 3.2.2. Inhibitory Effects of Selaginellins on UGT Activity {#sec3dot2dot2-molecules-22-01590}

The inhibitory effects of two selaginellins on the metabolism of six UGT probe substrates were evaluated using previously reported method with minor modification \[[@B34-molecules-22-01590]\]. In brief, HLMs (0.25 mg/mL) were activated by incubation in the presence of alamethicin (25 μg/mL) for 15 min on ice. After the addition of UGT isoform-selective substrates and selaginellins (0, 0.5, 2, 5, 20 and 50 μM) the final concentrations of organic solvent (methanol) for the cocktail incubation conditions were 1.0% (*v*/*v*). The incubation reaction mixtures were pre-incubated for 5 min. The reaction was initiated by the addition of 5 mM UDPGA and further incubated for 60 min. All reactions were terminated by adding ice-cold acetonitrile containing estrone glucuronide (IS). After mixing and centrifugation, aliquots were injected into a LC-MS/MS as described previously \[[@B34-molecules-22-01590]\] ([Table 2](#molecules-22-01590-t002){ref-type="table"}). All microsomal incubations were performed in triplicate.

3.3. Data Analysis {#sec3dot3-molecules-22-01590}
------------------

The IC~50~ values (concentration of the inhibitor causing 50% inhibition of the original enzyme activity) were calculated using WinNonlin software (Pharsight, Mountain View, CA, USA): percentage of control activity = 100 × \[1 − (I/(I + IC~50~))\], where I is the inhibitor concentration, and IC~50~ is the inflection point on the curve \[[@B34-molecules-22-01590]\].
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![Chemical structures of selaginellin and selaginellin M from *S. tamariscina*: (**a**) Selaginellin; (**b**) Selaginellin M.](molecules-22-01590-g001){#molecules-22-01590-f001}

###### 

Inhibitory effects of selaginellin and selaginellin M against ten cytochromes P450 (**A**,**B**) and six uridine 5′-diphosphoglucuronosyltransferase enzymes (**C**). The activity is expressed as the percentage of the control activity. The data are shown as mean ± S.D. (*n* = 3).
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molecules-22-01590-t001_Table 1

###### 

Inhibitory effects of selaginellin and selaginellin M against ten cytochrome P450 (P450) and six uridine 5′-diphosphoglucuronosyl transferase (UGT) isoforms.

  Compound         IC~50~ (μM)                                                                                             
  ---------------- ------------- ------ ------ ----- ----- ------ ----- ------ ----- ------ ----- ----- ----- ------ ----- ------
  Selaginellin     36.4          \>50   10.7   0.5   1.2   10.0   5.8   38.5   0.8   11.7   1.0   4.7   6.6   25.3   8.7   15.6
  Selaginellin M   \>50          \>50   11.3   0.9   3.9   16.1   6.8   \>50   2.7   \>50   1.3   3.5   3.9   36.5   6.5   10.4

molecules-22-01590-t002_Table 2

###### 

Selected reaction monitoring (SRM) parameters for the metabolites of ten cytochrome P450 and six uridine 5′-diphosphoglucuronosyltransferase probe substrates.

  Enzyme    Substrate               Concentration (μM)   Metabolite                          Transition (*m*/*z*)   Collision Energy (eV)   Polarity \*
  --------- ----------------------- -------------------- ----------------------------------- ---------------------- ----------------------- -------------
  CYP1A2    Phenacetin              100                  Acetaminophen                       152 \> 110             25                      ESI^+^
  CYP2A6    Coumarin                5.0                  Hydroxycoumarin                     163 \> 107             17                      ESI^+^
  CYP2B6    Bupropion               50                   Hydroxybupropion                    256 \> 238             20                      ESI^+^
  CYP2C8    Amodiaquine             1.0                  *N*-Desethylamodiaquine             328 \> 283             17                      ESI^+^
  CYP2C9    Tolbutamide             100                  Hydroxytolbutamide                  287 \> 89              42                      ESI^+^
  CYP2C19   Omeprazole              20                   Hydroxyomeprazole                   362 \> 214             10                      ESI^+^
  CYP2D6    Dextromethorphan        5.0                  Dextrorphan                         258 \> 157             35                      ESI^+^
  CYP2E1    Chlorzoxazone           50                   Hydroxychlorzoxazone                184 \> 120             15                      ESI^−^
  CYP2J2    Astemizole              1.0                  *O*-Desmethyl astemizole            445 \> 204             35                      ESI^+^
  CYP3A     Midazolam               5.0                  Hydroxymidazolam                    342 \> 203             25                      ESI^+^
  UGT1A1    SN-38                   0.5                  SN-38-glucuronide                   569 \> 393             30                      ESI^+^
  UGT1A3    Chenodeoxycholic acid   2.0                  Chenodeoxycholic acid glucuronide   567 \> 391             35                      ESI^−^
  UGT1A4    Trifluoperazine         0.5                  Trifluoperazine glucuronide         584 \> 408             25                      ESI^+^
  UGT1A6    *N*-Acetylserotonin     1.0                  *N*-Acetylserotonin glucuronide     395 \> 219             15                      ESI^+^
  UGT1A9    Mycophenolic acid       0.2                  Mycophenolic acid glucuronide       495 \> 319             20                      ESI^−^
  UGT2B7    Naloxone                1.0                  Naloxone glucuronide                504 \> 310             30                      ESI^+^

\* Electrospray ionization in positive mode (ESI^+^) and negative mode (ESI^−^).
